Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 11Pancreatic Neoplasms 4Multiple Myeloma 4Urinary Bladder Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Digestive System Neuroendocrine Tumor G1 × Sunitinib × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡